UBS has downgraded Gildan Activewear to a neutral rating, signaling that the apparel maker's path back to growth may be longer and bumpier than previously expected. The move follows a weaker-than-expected fiscal third quarter and a reduced outlook for fiscal 2026, with the bank warning that headwinds could persist well into 2027.
What happened
Gildan, a major manufacturer of basic apparel like t-shirts and socks, reported fiscal Q3 results that missed analyst expectations on both sales and profits. UBS noted that the weakness was broad-based, suggesting the slowdown is hitting harder than the market had assumed. The bank also pointed to supply chain frictions and an unfavorable product mix in Gildan's retail business, which it believes could linger into the second half of 2027 and keep revenue growth muted.
As a result, UBS now sees no obvious near-term catalyst for the stock and warns that a "sustainable" sales rebound could slip toward 2028. To reflect this, the bank cut its earnings per share (EPS) forecast for fiscal 2026 to $3.70 from $4.55, and for fiscal 2027 to $3.25 from $5.45. It also slashed its price target to $38 from $71, while the stock was trading around $35.
Why the downgrade matters
Gildan has long been a staple in the basics segment of the apparel industry, selling to wholesale distributors, screen printers, and retailers. Its products are often seen as a barometer for consumer spending on everyday clothing. When a company like Gildan struggles, it can signal broader caution among consumers, who may be cutting back on discretionary purchases.
The downgrade also highlights how quickly sentiment can shift. Just a few months ago, analysts were more optimistic about Gildan's recovery. Now, UBS is essentially saying that the company's problems are not just temporary blips but could extend for another couple of years. For investors, this means the stock may not see a meaningful rebound in the near term.
What it means for investors
Price targets are not just about profits; they also embed what analysts think a stock is worth per dollar of earnings. With UBS's new numbers, the $38 target implies a forward price-to-earnings (P/E) ratio of roughly 10.3 ($38 divided by $3.70), versus about 15.6 under the old $71 and $4.55 assumptions. And with the shares already near $35, the stock is sitting around 9.5 times UBS's 2026 earnings estimate, which leaves less room for the kind of "rerating" that happens when investors decide to pay a higher multiple.
In other words, unless the sales outlook improves enough to lift earnings forecasts, the upside case increasingly depends on results, not sentiment. This is a common situation for companies in turnaround mode: the market may have already priced in a recovery, and if that recovery is delayed, the stock can languish.
For everyday investors, this downgrade is a reminder that even well-known brands can face prolonged slumps. It also underscores the importance of looking beyond a company's current earnings to understand the trajectory of its business. A stock can look cheap on a P/E basis, but if earnings are expected to fall, the apparent value may be misleading.
UBS's move is not an isolated event. Other companies have recently faced similar downgrades due to extended recovery timelines. For example, BofA warned that FIS's profit recovery could drag into 2028, highlighting that some firms are struggling to regain momentum. Similarly, Sanrio's dividend cut signals caution despite strong Hello Kitty sales, showing that even growth can come with caveats.
Investors should also consider the broader retail environment. Costco's October sales jumped even as consumer stocks slipped, indicating that while some retailers are thriving, others are facing headwinds. Gildan's challenges may be company-specific, but they also reflect a consumer who is becoming more selective.
Looking ahead
The key question for Gildan is whether management can address the supply chain issues and improve product mix to reignite growth. UBS's downgrade suggests that the market should not expect a quick fix. For now, the stock may trade in a range, with investors waiting for signs that the company can turn things around.
As always, it's important to remember that analyst ratings are just one piece of the puzzle. They reflect a particular view at a particular time, and they can change. For those holding Gildan shares, the downgrade is a signal to reassess expectations. For those considering buying, it may be worth waiting for more clarity on the company's recovery path.
